Skip to main content
SpringerLink
Log in

Risk Stratification in Waldenström Macroglobulinemia

  • Chapter
  • First Online:
Waldenström’s Macroglobulinemia

  • 573 Accesses

Abstract

Waldenström macroglobulinemia (WM) is defined by the production of serum monoclonal immunoglobulin M and lymphoplasmacytic bone marrow infiltration. In addition, a specific molecular abnormality, the MYD88L265P mutation, is present in up to 90 % of patients. WM comprises a heterogeneous population of patients with markedly different evolutions, from indolent courses to rapidly progressing disease. At least 25 % of patients are asymptomatic at diagnosis, and treatment is mandatory in cases of symptomatic disease only. Although, the International Prognostic System for WM has been based on patient populations treated before the availability of many recent agents now used for treatment of WM patients, this index remains the most effective and validated tool for stratifying patients for initial therapy. More research on the biology of the disease is warranted in order to identify additional prognostic factors for predicting outcome, taking the dramatic improvement in survival of patients with symptomatic WM into account.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–5.

    Article  PubMed  Google Scholar 

  2. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  3. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.

    Article  CAS  PubMed  Google Scholar 

  4. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom’s macroglobulinemia: a report of 167 cases. J Clin Oncol. 1993;11:1553–8.

    Article  CAS  PubMed  Google Scholar 

  5. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575–82.

    Article  CAS  PubMed  Google Scholar 

  6. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852–8.

    CAS  PubMed  Google Scholar 

  7. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom’s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939–45.

    CAS  PubMed  Google Scholar 

  8. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001;98:41–8.

    Article  CAS  PubMed  Google Scholar 

  9. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006;133:158–64.

    Article  PubMed  Google Scholar 

  10. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.

    Article  CAS  PubMed  Google Scholar 

  11. Gertz MA. Waldenstrom macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86:411–6.

    Article  PubMed  Google Scholar 

  12. Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood. 2009;113:793–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom’s macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737–42.

    Article  CAS  PubMed  Google Scholar 

  14. Morel P, Merlini G. Risk stratification in Waldenstrom macroglobulinemia. Expert Rev Hematol. 2012;5:187–99.

    Article  CAS  PubMed  Google Scholar 

  15. Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: a population-based study of 1555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013;88:60–5.

    Article  PubMed  Google Scholar 

  16. Castillo JJ, Olszewski AJ, Kanan S, et al. Survival outcomes of secondary cancers in patients with Waldenstrom macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015;90:696–701.

    Article  PubMed  Google Scholar 

  17. Kastritis E, Kyrtsonis MC, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenstrom’s macroglobulinemia treated over the last 25 years. Am J Hematol. 2011;86:479–83.

    Article  PubMed  Google Scholar 

  18. Varettoni M, Tedeschi A, Arcaini L, et al. Risk of second cancers in Waldenstrom macroglobulinemia. Ann Oncol 2012;23(2):411–415.

    Google Scholar 

  19. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250–5.

    Article  PubMed  Google Scholar 

  20. Stalnikiewicz L, Carrotte-Lefebvre I, Detourmignies L, et al. Prognostic factors in Waldenstrom’s macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients. Semin Oncol. 2003;30:216–9.

    Article  PubMed  Google Scholar 

  21. Leblond V, Lejeune J, Tournilhac O, et al. International phase III study of chlorambucil versus fludarabine as initial therapy for Waldenström’s macroglobulinemia and related disorders: results in 414 patients on behalf of FCGCLL/WM, GOELAMS, GELA and NCRI Annals Oncol 2011;22:134.

    Google Scholar 

  22. Dimopoulos MA, Kastritis E, Delimpassi S, et al. The international prognostic scoring system for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93:1420–2.

    Article  CAS  PubMed  Google Scholar 

  23. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30:211–5.

    Article  PubMed  Google Scholar 

  24. Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res. 2005;11:1786–90.

    Article  CAS  PubMed  Google Scholar 

  25. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:116–20.

    Article  PubMed  Google Scholar 

  26. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:17–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cesana C, Miqueleiz S, Bernuzzi P, et al. Smouldering Waldenstrom’s macroglobulinemia: factors predicting evolution to symptomatic disease. Semin Oncol. 2003;30:231–5.

    Article  PubMed  Google Scholar 

  28. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom’s macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23:4662–8.

    Article  PubMed  Google Scholar 

  29. Itzykson R, Le Garff-Tavernier M, Katsahian S, et al. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobulinemia. Haematologica. 2008;93:793–4.

    Article  PubMed  Google Scholar 

  30. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J Clin Oncol. 2005;23:474–81.

    Article  CAS  PubMed  Google Scholar 

  31. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1570–5.

    Article  CAS  PubMed  Google Scholar 

  32. Dimopoulos MA, Alexanian R, Gika D, et al. Treatment of Waldenstrom’s macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma. 2004;45:2057–61.

    Article  CAS  PubMed  Google Scholar 

  33. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al. Waldenstrom’s macroglobulinemia: clinical course and prognostic factors in 60 patients: experience from a single hematology unit. Ann Hematol. 2001;80:722–7.

    Article  CAS  PubMed  Google Scholar 

  34. Weber DM, Dimopoulos MA, Delasalle K, et al. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30:243–7.

    Article  CAS  PubMed  Google Scholar 

  35. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood. 2009;113:3673–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 2005;90:700–2.

    CAS  PubMed  Google Scholar 

  37. Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstrom’s macroglobulinemia: results in 49 patients. Leukemia. 2005;19:1831–4.

    Article  CAS  PubMed  Google Scholar 

  38. Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003;44:993–6.

    Article  CAS  PubMed  Google Scholar 

  39. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276–82.

    Article  CAS  PubMed  Google Scholar 

  40. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27:3830–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood. 2015;126:1392–4.

    Article  PubMed  Google Scholar 

  42. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol. 2010;85:670–4.

    Article  CAS  PubMed  Google Scholar 

  43. Johnson SA. Waldenstrom’s macroglobulinemia. Rev Clin Exp Hematol. 2002;6:421–34. Discussion 449–50.

    Article  CAS  PubMed  Google Scholar 

  44. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047–55.

    Article  CAS  PubMed  Google Scholar 

  45. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom’s macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–33.

    Article  CAS  PubMed  Google Scholar 

  46. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79–85.

    CAS  PubMed  Google Scholar 

  47. Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001;98:2640–4.

    Article  CAS  PubMed  Google Scholar 

  48. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344–9.

    Article  CAS  PubMed  Google Scholar 

  49. Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420–8.

    Article  CAS  PubMed  Google Scholar 

  50. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom’s macroglobulinemia. Ann Oncol. 2003;14:1299–305.

    Article  CAS  PubMed  Google Scholar 

  51. Anagnostopoulos A, Zervas K, Kyrtsonis M, et al. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom’s macroglobulinemia requiring treatment. Clin Lymphoma Myeloma. 2006;7:205–9.

    Article  CAS  PubMed  Google Scholar 

  52. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol. 2009;27:120–6.

    Article  PubMed  Google Scholar 

  53. Kastritis E, Kyrtsonis MC, Hadjiharissi E, et al. Validation of the international prognostic scoring system (IPSS) for Waldenstrom’s macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340–3.

    Article  CAS  PubMed  Google Scholar 

  54. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol. 2007;137:560–8.

    Article  CAS  PubMed  Google Scholar 

  55. Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor (VWF) in Waldenstrom macroglobulinemia (WM) Patients (pts). A Clinicopathological Study on 72 Pts. ASH Annual Meeting Abstracts 116:2438, 2010.

    Google Scholar 

  56. Nguyen-Khac F, Lejeune J, Chapiro E, et al. Cytogenetic abnormalities in a cohort of 171 patients with Waldenstrom macroglobulinemia before treatment: clinical and biological correlations. ASH Annual Meeting Abstracts 116:801, 2010.

    Google Scholar 

  57. Poulain S, Dervite I, Leleu X, et al. The IL6(−174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less. Haematologica. 2008;93:1109–11.

    Article  CAS  PubMed  Google Scholar 

  58. Poulain S, Ertault M, Leleu X, et al. SDF1/CXCL12 (−801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia. Leuk Res. 2009;33:1204–7.

    Article  CAS  PubMed  Google Scholar 

  59. Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791–6.

    Article  CAS  PubMed  Google Scholar 

  60. Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood. 2009;113:4391–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s Macroglobulinemia. Clin Lymphoma Myeloma. 2006;6:380–3.

    Article  PubMed  Google Scholar 

  62. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:53–5.

    Article  PubMed  Google Scholar 

  63. Treon SP, Yang G, Hanzis C, et al. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154:223–8.

    Article  PubMed  Google Scholar 

  64. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28:2227–32.

    Article  CAS  PubMed  Google Scholar 

  65. Gertz MA, Abonour R, Heffner LT, et al. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009;147:677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Hivert B, Tamburini J, Vekhoff A, et al. Prognostic value of the international scoring system and response in patients with advanced Waldenström macroglobulinemia. Haematologica. 2011;96:785–8.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014;28:1698–704.

    Article  CAS  PubMed  Google Scholar 

  68. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom’s macroglobulinemia: a report of 71 cases: Groupe Cooperatif Macroglobulinemie. J Clin Oncol. 1998;16:2060–4.

    Article  CAS  PubMed  Google Scholar 

  69. Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010;28:2233–8.

    Article  CAS  PubMed  Google Scholar 

  70. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer [Epub ahead of print]. 2011.

    Google Scholar 

  71. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1422–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Treon SP, Xu L, Xu Z. MYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373:584–6.

    Article  CAS  PubMed  Google Scholar 

  73. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2010;16:1033–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120–31.

    Article  CAS  PubMed  Google Scholar 

  75. Ghobrial IM, Redd R, Armand P, et al. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015;29(12):2338–46.

    Article  CAS  PubMed  Google Scholar 

  76. Levy V, Morel P, Porcher R, et al. Advanced Waldenstrom’s macroglobulinemia: usefulness of Morel’s scoring system in establishing prognosis. Haematologica. 2005;90:279–81.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hématologie, Centre Hospitalier Schaffner, Lens, France

    Pierre Morel & Bénédicte Hivert

  2. Department of Biostatistics, Equipe d’Accueil 2694, University Lille Nord de France, Lille, France

    Pierre Morel

  3. Service d’Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire d’Amiens, Amiens, France

    Pierre Morel

Authors
  1. Pierre Morel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bénédicte Hivert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Morel .

Editor information

Editors and Affiliations

  1. Haematology, Hôpital Pitié-Salpêtriêre, Paris, France

    Véronique Leblond

  2. Dana Farber Cancer Institute, Boston, Massachusetts, USA

    Steve Treon

  3. School of Medicine, University of Athens, Athens, Greece

    Meletios Dimoploulos

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morel, P., Hivert, B. (2017). Risk Stratification in Waldenström Macroglobulinemia. In: Leblond, V., Treon, S., Dimoploulos, M. (eds) Waldenström’s Macroglobulinemia. Springer, Cham. https://doi.org/10.1007/978-3-319-22584-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22584-5_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22583-8

  • Online ISBN: 978-3-319-22584-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation